Alder announces positive results from pharmacokinetic comparability study for eptinezumab
Alder Biopharmaceuticals announced positive results from a comparative PK study intended to support the comparability evaluation of the clinical supply for eptinezumab and its planned commercial supply. Eptinezumab is Alder’s lead investigational product candidate for migraine prevention. October 23, 2018